CAPTRUST Financial Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-180	Closed	-$9K	–	2283
2022 Q2	$9K	Hold	180	–	–	﹤0.01%	3789
2022 Q1	$11K	Hold	180	–	–	﹤0.01%	3733
2021 Q4	$15K	Hold	180	–	–	﹤0.01%	3468
2021 Q3	$17K	Hold	180	–	–	﹤0.01%	3264
2021 Q2	$18K	Hold	180	–	–	﹤0.01%	3164
2021 Q1	$15K	Hold	180	–	–	﹤0.01%	3181
2020 Q4	$16K	Hold	180	–	–	﹤0.01%	2346
2020 Q3	$13K	Hold	180	–	–	﹤0.01%	2170
2020 Q2	$13K	Buy	+180	New	+$11.5K	﹤0.01%	2089
2019 Q4	–	Sell	-180	Closed	-$8K	–	1088
2019 Q3	$8K	Hold	180	–	–	﹤0.01%	1556
2019 Q2	$9K	Hold	180	–	–	﹤0.01%	1520
2019 Q1	$10K	Hold	180	–	–	﹤0.01%	1378
2018 Q4	$8K	Hold	180	–	–	﹤0.01%	1255
2018 Q3	$13K	Hold	180	–	–	﹤0.01%	1148
2018 Q2	$10K	Hold	180	–	–	﹤0.01%	1163
2018 Q1	$9K	Hold	180	–	–	﹤0.01%	1045
2017 Q4	$10K	Hold	180	–	–	﹤0.01%	977
2017 Q3	$10K	Buy	180 +80	+80%	+$4.55K	﹤0.01%	433
2017 Q2	$5K	Buy	+100	New	+$4.88K	﹤0.01%	240

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Capital Investment Advisors Atlanta, Georgia $7.74B AUM 15.52% 1-Year Est. Return

Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

CAPTRUST Financial Advisors's BIB Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2022, closing a stake of 180 shares — an estimated $9K sold.

CAPTRUST Financial Advisors first reported a position in BIB in Q2 2017 and held it in 19 quarters. The position peaked at $18K in Q2 2021. 19 funds tracked by Wall St. Rank hold BIB as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 180 ProShares Ultra NASDAQ Biotechnology shares in Q3 2022, an estimated $9K.
CAPTRUST Financial Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2017 and held it in 19 quarters.
CAPTRUST Financial Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $18K in Q2 2021.
19 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.